No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
UTHR240719P290000
- 0.80
- -0.32-28.57%
15min DelayClose Jul 5 16:00 ET
1.33High0.80Low
1.33Open1.12Pre Close5 Volume239 Open Interest290.00Strike Price453.00Turnover31.54%IV8.06%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type-0.0863Delta0.0080Gamma393.20Leverage Ratio-0.1031Theta-0.0098Rho-33.92Eff Leverage0.0979Vega
Intraday
- 5D
- Daily
News
United Therapeutics(UTHR.US) Officer Sells US$2.27 Million in Common Stock
$United Therapeutics(UTHR.US)$ Officer ROTHBLATT MARTINE A sold 7,200 shares of common stock on Jul 2, 3, 2024 at an average price of $315.3531 for a total value of $2.27 million.Source: Announcement
United Therapeutics(UTHR.US) Officer Sells US$2.3 Million in Common Stock
$United Therapeutics(UTHR.US)$ Officer ROTHBLATT MARTINE A sold 7,200 shares of common stock on Jun 28, Jul 1, 2024 at an average price of $319.5054 for a total value of $2.3 million.Source: Announcem
United Therapeutics(UTHR.US) Director Sells US$2.4 Million in Common Stock
$United Therapeutics(UTHR.US)$ Director Thompson Tommy G sold 7,500 shares of common stock on Jun 26, 2024 at an average price of $319.3381 for a total value of $2.4 million.Source: Announcement What
United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing
Martine A Rothblatt, Director, Chairperson & CEO, on June 26, 2024, sold 7,200 shares in United Therapeutics (UTHR) for $2,285,941. Following the Form 4 filing with the SEC, Rothblatt has control over
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
Oppenheimer analyst Andreas Argyrides maintains $United Therapeutics(UTHR.US)$ with a buy rating, and adjusts the target price from $308 to $400.According to TipRanks data, the analyst has a success r
Express News | United Therapeutics Corporation Announces Election of Jan Malcolm to Its Board of Directors
Comments
$United Therapeutics(UTHR.US$
lol that is a shit ton of inside selling all at the end of June
lol that is a shit ton of inside selling all at the end of June
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
12
1
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
Are you a high net profit margin lover? So you will like these 1⃣2⃣ stocks with a net profit margin above 4⃣0⃣%
🇺🇸 Texas Pacific Land $Texas Pacific Land(TPL.US$ 63.3%
🇸🇪 Evolution $Evotec(EVO.US$ 59.3%
🇺🇸 CME Group $CME Group(CME.US$ 57.1%
🇺🇸 Visa $Visa(V.US$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR(RTMVY.US$ 54.8%
🇺🇸 Verisign $VeriSign(VRSN.US$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise(PME.US$ 49.8%
🇺🇸 NVidia $NVIDIA(NVDA.US$ 47.3%
🇺🇸 Mastercard $MasterCard(MA.US$ 45.1%
🇫🇷 GTT $GTT Communications, Inc.(GTTN.US$ 44.8% ...
🇺🇸 Texas Pacific Land $Texas Pacific Land(TPL.US$ 63.3%
🇸🇪 Evolution $Evotec(EVO.US$ 59.3%
🇺🇸 CME Group $CME Group(CME.US$ 57.1%
🇺🇸 Visa $Visa(V.US$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR(RTMVY.US$ 54.8%
🇺🇸 Verisign $VeriSign(VRSN.US$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise(PME.US$ 49.8%
🇺🇸 NVidia $NVIDIA(NVDA.US$ 47.3%
🇺🇸 Mastercard $MasterCard(MA.US$ 45.1%
🇫🇷 GTT $GTT Communications, Inc.(GTTN.US$ 44.8% ...
13
The low P/E despite solid growth numbers seems to stem from investor sentiment, possibly from certain unobserved threats affecting the stock. Some shareholders might be skeptical of the earnings forecasts, indicating potential earnings instability.
Read more